Ignite Creation Date:
2025-12-25 @ 1:32 AM
Ignite Modification Date:
2026-03-09 @ 8:12 AM
Study NCT ID:
NCT02220894
Status:
COMPLETED
Last Update Posted:
2023-10-10
First Post:
2014-08-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-10-30
Start Date Type:
ACTUAL
Primary Completion Date:
2018-09-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-09-12
Completion Date Type:
ACTUAL
First Submit Date:
2014-08-19
First Submit QC Date:
None
Study First Post Date:
2014-08-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-02-14
Results First Submit QC Date:
None
Results First Post Date:
2019-03-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-06
Last Update Post Date:
2023-10-10
Last Update Post Date Type:
ACTUAL